US 11,944,811 B1
Electrical therapy applied to the brain with increased efficacy and/or decreased undesirable side effects, and associated systems and methods
Satinderpall Singh Pannu, Redwood City, CA (US); and Bradford Evan Gliner, Sammamish, WA (US)
Assigned to Nevro Corp., Redwood City, CA (US)
Filed by Nevro Corp., Redwood City, CA (US)
Filed on Jul. 28, 2021, as Appl. No. 17/387,375.
Application 17/387,375 is a continuation of application No. 16/663,255, filed on Oct. 24, 2019, granted, now 11,123,549.
Application 16/663,255 is a continuation of application No. 16/127,098, filed on Sep. 10, 2018, abandoned.
Claims priority of provisional application 62/643,128, filed on Mar. 14, 2018.
Claims priority of provisional application 62/556,183, filed on Sep. 8, 2017.
Int. Cl. A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61N 1/08 (2006.01); A61B 5/291 (2021.01)
CPC A61N 1/0534 (2013.01) [A61N 1/0531 (2013.01); A61N 1/36082 (2013.01); A61B 5/291 (2021.01); A61N 1/36064 (2013.01); A61N 1/36171 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A method for treating a patient, comprising:
programming an implantable signal generator to deliver an electrical signal to a target neural population in the patient's brain, via an implanted signal delivery device, to reduce or eliminate the effects of a patient disorder and without the electrical signal inducing paresthesia,
wherein the electrical signal has a frequency in a frequency range of from 5 kHz to 500 kHz, an amplitude in an amplitude range of from 0.1 mA to 20 mA, and a pulse width in a pulse width range of from 10 microseconds to 333 microseconds.